Cargando…
Prevalence of hypercalcemia among cancer patients in the United States
Hypercalcemia of malignancy (HCM) is a serious metabolic complication whose population‐based prevalence has not been quantified. Rates of HCM differ by tumor type, with highest rates reported in multiple myeloma and lowest among colorectal and prostate cancer patients. This analysis estimates HCM pr...
Autores principales: | Gastanaga, Victor M., Schwartzberg, Lee S., Jain, Rajul K., Pirolli, Melissa, Quach, David, Quigley, Jane M., Mu, George, Scott Stryker, W., Liede, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899051/ https://www.ncbi.nlm.nih.gov/pubmed/27263488 http://dx.doi.org/10.1002/cam4.749 |
Ejemplares similares
-
Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States
por: Arellano, Jorge, et al.
Publicado: (2015) -
Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States
por: McGrath, Leah J., et al.
Publicado: (2018) -
Prevalence of hypercalcemia of malignancy among pediatric cancer patients in the UK Clinical Practice Research Datalink database
por: Jick, Susan, et al.
Publicado: (2017) -
Midlife brain metastases in the United States: Is male at risk?
por: Che, Wenqiang, et al.
Publicado: (2022) -
Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial‐ethnic group, United States 2003‐2016
por: Ellington, Taylor D., et al.
Publicado: (2020)